Jianping Xiong

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu et al. · Journal of Clinical Oncology · 2016 · 976 citations

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Yoon‐Koo Kang, Won Ki Kang, D.B. Shin et al. · Annals of Oncology · 2009 · 773 citations · Full text

First-line Therapy, Surgical Oncology, Gastrointestinal Oncology +7

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng et al. · The Lancet Oncology · 2020 · 625 citations

Hepatology, Medicine, Pathology +6

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu et al. · The Lancet · 2023 · 590 citations

First-line Therapy, Hepatology, International Phase 3 +8

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen et al. · The Lancet Oncology · 2020 · 568 citations

Esophageal Cancer, Gastrointestinal Oncology, Medicine +10